Many valuable drug development opportunities, either from academia or from discovery-focused biotech companies, lose their way in development and never reach the patients who should benefit from them. Small Pharma is dedicated to identifying these opportunities and ensuring that the value in the underlying pharmaceutical assets is preserved.

With specific experience in IP and the drug development process, we integrate a robust IP strategy with the development plan required to

guide close-to-clinic candidates through the clinical trials necessary to demonstrate proof-of-concept in patients.

The Small Pharma team are highly qualified, with specific experience in both IP and the drug development process.

Our model progresses projects that:

  1. have supportive biological evidence

  2. have further potential for defensible IP

  3. are areas of significant unmet need